GRM3
Metabotropic glutamate receptor 3
As of the edition of 20 October 2026, GRM3 (metabotropic glutamate receptor 3, UniProt Q14832) has 6 drugs tested at it and 5 companies on the list, 5 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q14832
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 20
- Disease areas
- Mental health; Digestive system
- Registered trials of its drugs
- 35
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 5 |
| Stopped | 1 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Pomaglumetad methionil anhydrous | Stopped | Phase 3 | none listed |
| Decoglurant | Went quiet | Phase 2 | none listed |
| TS-134 | Went quiet | Phase 1 | none listed |
| LY404039 | Went quiet | Phase 1 | none listed |
| MGS-0210 | Went quiet | Phase 1 | none listed |
| LY2969822 | Went quiet | Phase 1 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Denovo Biopharma | Route A |
| Eli Lilly | Route A |
| Roche | Route A |
The other 2 companies at GRM3
In the product5 companies in all; 2 are not named here, and no score is.
See the 5 companies at GRM3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.